Jamieson, Andrew - University of Glasgow

个人简介

Andrew Jamieson was born in Glasgow and raised in Strathaven, Scotland. In 2003, he completed a BSc Honours degree (1st Class) in Chemistry with Medicinal Chemistry at the University of Glasgow. He subsequently studied for a Ph.D. at the University of Glasgow under the supervision of Dr Andrew Sutherland. The aim of his Ph.D. was to investigate a new substrate directed, palladium-catalysed aza-Claisen rearrangement, and utilise this novel reaction for the synthesis of natural products. In 2007, he took up a postdoctoral research fellowship with Professor William Lubell at the University of Montreal, Canada. During this time he developed a novel synthetic method with which to systematically scan peptides for secondary structure. His research emphasis was determining the bioactive conformation of the growth hormone secretagogue, GHRP-6, as well as the allosteric modulator of the IL-1 receptor, 101.10 (rytvela). In 2008, he took up a postdoctoral position with Professor Andrew Hamilton FRS at Yale University, USA. While there he worked on the design and synthesis of a novel peptide beta-strand mimetic, before moving with Professor Hamilton in 2009 to the University of Oxford, UK. In August 2010, he was appointed to a lectureship in the Centre for Chemical Biology in the Department of Chemistry at the University of Leicester, UK. He was then appointed as a senior lecturer in Chemical Biology at the University of Glasgow School of Chemistry in July 2016. He currently runs a research group whose work focuses on the synthesis of peptides and peptidomimetics that can be used to probe the biological mechanisms of cancer and Alzheimer’s disease. Andrew’s main hobbies outside of chemical biology are running, rugby and snowboarding.

研究领域

We are particularly interested in the selective regulation of ion-channels by conotoxins with potential application in the treatment of severe pain. We are also investigating the structural activation and substrate binding of deubiquitinase (DUB) and histone deacetylase (HDAC) enzymes and developing novel peptide based inhibitors. We are also attempting to determine the structure of toxic amyloid proteins that are proposed to be the underlying cause of Alzheimer’s disease.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

P. J. Watson, C. J. Millard, A. M. Riley, N. S. Robertson, L. C. Wright, H. Y. Godage, S. M. Cowley, A. G. Jamieson, B. V. L. Potter, John W. R. Schwabe, The mechanism of activation of class I HDAC complexes by inositol phosphates. Nat. Commun., 2016, 7, 11262 (DOI: 10.1038/ncomms11262) M. J. Burton, S. M. Kapetanaki, R. C. Stratton, A. G. Jamieson, N. W. Davies, J. S. Mitcheson, R. Schmid, P. C. E. Moody, E. L. Raven, N. M. Storey, Heme modulates cardiac KATP channel function., PNAS, 2016, 113, 3785–3790. N. Allaway, A. G. Jamieson, Regulation of Protein-Protein Interactions using Stapled Peptides. Rep. Org Chem., 2015, 5, 65 - 74. B. Aillard, N. S. Robertson, A. R. Baldwin, S. Robins, A. G. Jamieson, Robust Asymmetric Synthesis of Unnatural Alkenyl Amino Acids for Conformationally Constrained alpha-Helix Peptides. Org. Biomol. Chem., 2014, 12, 8775.